ACADIA Pharmaceuticals (ACAD)
(Delayed Data from NSDQ)
$22.70 USD
-0.04 (-0.18%)
Updated Oct 31, 2025 04:00 PM ET
After-Market: $22.68 -0.02 (-0.09%) 7:58 PM ET
2-Buy of 5 2
B Value C Growth D Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
Currently, ACADIA Pharmaceuticals Inc. has a PEG ratio of 6.54 compared to the Medical - Biomedical and Genetics industry's PEG ratio of 1.58.
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ACAD 22.70 -0.04(-0.18%)
Will ACAD be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for ACAD based on the 1-3 month trading system that more than doubles the S&P 500.

Zacks News for ACAD
Analysts Estimate Acadia Pharmaceuticals (ACAD) to Report a Decline in Earnings: What to Look Out for
Acadia (ACAD) Moves to Buy: Rationale Behind the Upgrade
ACAD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Does Acadia (ACAD) Have the Potential to Rally 27.66% as Wall Street Analysts Expect?
Is HCA HEALTHCARE (HCA) Stock Outpacing Its Medical Peers This Year?
QGEN vs. ACAD: Which Stock Is the Better Value Option?
Other News for ACAD
Is ACAD showing upside potential? MACD Bullish Centerline Cross shows up after sliding 0.18%
ACAD rises 0.93% on October 30, leaving the technical picture intact
ACAD's price falls by 0.4% on October 29, though its technical setup remains stable.
ACADIA Pharmaceuticals Advances Alzheimer’s Disease Psychosis Study with ACP-204
Is ACAD ready to make a move? NR7 shows up after dropping 1.61%